GlobeNewswire by notified

Pixium Vision announces the 48-Month Trial Results in Severe Atrophic AMD


Pixium Vision announces the 48-Month Trial Results in Severe Atrophic AMD

  • Study confirms subretinal prothesis feasible and well-tolerated with no reduction of natural peripheral vision, confirming 36-month results
  • Patients suffering from central vision loss reliably recognized letters and sequences of letters, a clinically significant improvement
  • Full data readout of accompanying pivotal PRIMAvera trial expected early 2024
  • Pixium Vision reiterates that it is subject to receivership proceedings and is actively seeking buyers for its assets

Paris, France, 14, 2023 – 7:00 am (CET) – Pixium Vision SA (Euronext Growth Paris - FR001400JX97; Mnemo: ALPIX), a bioelectronics company developing innovative vision systems to enable patients who have lost their sight to live more independent lives, today announces data from a first in human trial to assess the efficacy and safety of the PRIMA photovoltaic retinal stimulation microchip for improving visual acuity (VA) 48 months post implantation in patients with severe central vision impairment due to dry age-related macular degeneration (dry AMD)

The trial data show that the implantation of PRIMA is feasible and well tolerated in all five study participants, with no reduction of natural peripheral visual function after 48 months. Using the prosthetic central vision provided by PRIMA, patients reliably recognized letters and sequences of letters with a clinically meaningful improvement in visual acuity of up to eight lines. The data currently undergoing journal peer review are available here.

In the beginning of Q2 2024 Pixium is expecting to report the full data readout from PRIMAvera, its European pivotal study, an open-label, baseline controlled, non-randomized, multi-center, prospective single-arm pivotal trial which has enrolled 38 patients (NCT04676854).

One of the major visual disabilities for patients with age-related macular degeneration (AMD) and geographic atrophy is the gradual decline and then a permanent loss of reading ability within the central field,” commented Professor Frank Holz, Scientific Coordinator of the study, “Unlike the current and potential pharmacological treatments for geographic atrophy, which aim to slow the growth of atrophic lesions without functional improvement in visual acuity, the PRIMA study results demonstrate restoration of central vision in the former scotoma. At the 4-year time-point, the mean gain was 32 letters, which corresponds to an improvement of logMAR 0.6 (six lines) and should be considered clinically meaningful for patients with geographic atrophy with foveal involvement secondary to AMD.”

We are delighted that thanks to our PRIMAvera pivotal study, 19 leading European retinal surgery sites have been trained in the minimally invasive procedure to implant our 2x2 mm photovoltaic sub-retinal microchip in under 2 hours” stressed Ralf Hornig, PhD Director of Clinical Affairs

Further improvements of the AR glasses will widen the visual field, while the advanced image processing and stimulation protocol promise even more functional restoration of sight for patients suffering from atrophic macular degeneration no longer treatable with Pegcetacoplan injections” predicted Daniel Palanker, the Department of Ophthalmology and Hansen Experimental Physics Laboratory at Stanford University CA USA, who is leading the engineering development of Pixium’s next generation chip.

The PRIMA retinal prosthesis includes a microchip, which is self-sustaining and needs no wires for external power supply, inserted under the fovea (central part of the retina). Each pixel of the implant (of which there are 378) independently converts light projected from transparent augmented-reality (AR) glasses into electric current stimulating the inner retinal cells, restoring vision in patients’ central blind spot. The retinal photovoltaic neurostimulation microchip is just 2-mm wide and 30-μm thick, carrying 378 electrodes of just 100 μm (1 μm = one millionth of a meter) in diameter.

As a reminder, the Company is currently subject to receivership proceedings and is actively looking for buyers to acquire the Company’s business. In that context, the Company draws investors’ attention to the possibility that, in the event of a court-ordered plan to sell off all or part of the Company’s assets, the price offered may not allow shareholders to be reimbursed in full or in part.

The deadline for submission of offers has been set to November 20, 2023, at 12:00 p.m. (noon) CET.

Pixium will continue to regularly inform the market on the progress of the procedure and, more generally, of Pixium Vision’s financial situation.

About Pixium Vision

Pixium Vision is creating a world of bionic vision for those who have lost their sight, enabling them to regain visual perception and greater autonomy. Pixium Vision’s bionic vision systems are associated with a surgical intervention and a rehabilitation period. Prima System sub-retinal miniature photovoltaic wireless implant is in clinical testing for patients who have lost their sight due to outer retinal degeneration, initially for atrophic dry age-related macular degeneration (dry AMD). Pixium Vision collaborates closely with academic and research partners, including some of the most prestigious vision research institutions in the world, such as Stanford University in California, Institut de la Vision in Paris, Moorfields Eye Hospital in London, Institute of Ocular Microsurgery (IMO) in Barcelona, University hospital in Bonn, and UPMC in Pittsburgh, PA. The Company is EN ISO 13485 certified and qualifies as “Entreprise Innovante” by Bpifrance.

Forward-Looking Statements. This press release contains certain forward-looking statements. Although the Company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. For a discussion of risks and uncertainties which could cause the Company's actual results, financial condition, performance or achievements to differ from those contained in the forward-looking statements, please refer to the Risk Factors (“Facteurs de Risques”) section of the Company’s 2022 Annual Financial Report and other documents the Company files with the AMF, which is available on the AMF website (www.amf- or on the Company’s website.

For more information:

Follow us on @PixiumVision;


Investor Relations

Pixium Vision
Offer Nonhoff
Chief Financial Officer

Media Relations

Rose Piquante Consulting
Sophie Baumont
+33 6 27 74 74 49


To view this piece of content from, please give your consent at the top of this page.
To view this piece of content from, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Oxurion Receives Transparency Notifications from Atlas Special Opportunities LLC1.12.2023 19:00:00 CET | Press release

Regulated Information Leuven, BELGIUM, Boston, MA, US – December 1, 2023 – 7.00 PM CET Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company developing next generation standard of care ophthalmic therapies, with clinical stage assets in vascular retinal disorders, today announced that, pursuant to Belgian Transparency legislation1 it has received transparency notifications as follows: Oxurion received a first transparency notification on November 22, 2023, from Atlas Special Opportunities, LLC indicating that as of November 13, 2023, it held 0 shares of the then outstanding 3,112,043,514 shares, and therefore crossed below the threshold (3%) by virtue of the sale of voting securities. See Annex 1. Oxurion received a second transparency notification on November 29, 2023, from Atlas Special Opportunities, LLC indicating that as of November 17, 2023, it held 241,545,893 shares of the then outstanding 3,489,458,972 shares, and therefore crossed above the threshold (5%) by virtu

Havila Kystruten AS: Regnskap for tredje kvartal 20231.12.2023 18:34:33 CET | Pressemelding

September var første måned med full drift av alle fire skip. Til tross for forsinkelse av Havila Polaris og Havila Pollux i Q3, ble gjennomsnittlig belegg 70 % og gjennomsnittlig lugarrate kr 4 466. Inntektene er naturligvis preget av forsinkelsene og lavere enn forventet, men selskapet ser en positiv inntektsutvikling fra 2. kvartal og videre ut året. I forbindelse med refinansiering er driftskostnadene påvirket av ekstraordinære kostnader knyttet til juridiske og finansielle rådgivere. Regnskap og balanse påvirkes av valutasvingningene, og selskapet sikrer sine valutaforpliktelser med salg i valuta. Selskapet legger til grunn en normalisert drift av fire skip fremover, uten ekstraordinære kostnader. Selskapet har ambisjoner om et gjennomsnittlig belegg på 80 % for 2024, hvorav 45 % av all kapasitet allerede er solgt. Interessen for Havila Kystruten øker stadig i både inn- og utland, og positive tilbakemeldinger om produkt og konsept mottas på daglig basis. Resultat for 3. kvartal 202

Havila Kystruten : Third quarter 2023 accounts1.12.2023 18:34:33 CET | Press release

September marked the first month of full operation for all four ships. Despite the delays with Havila Polaris and Havila Pollux in Q3, the average occupancy rate reached 70%, with an average cabin rate of NOK 4,466. Revenues are naturally affected by the delays and lower than expected, but the company sees a positive revenue trend from the 2nd quarter and onward throughout the year. In connection with refinancing, operating costs were affected by extraordinary expenses related to legal and financial advisors. Currency fluctuations have had an impact on the financial statements and balance sheet, and the company is hedging its currency commitments through currency sales. The company assumes normalized operation of four ships going forward, without extraordinary costs. The company aims for an average occupancy rate of 80% for 2024, with 45% of all capacity already sold. Interest in Havila Kystruten is continually growing both domestically and internationally, with positive feedback on th

Resultat af aktietilbagekøb1.12.2023 17:41:01 CET | pressemeddelelse

Selskabet meddelte i selskabsmeddelelse 30/2023, at man havde besluttet at iværksætte et aktietilbagekøb på køb af optil 1.000.000 aktier til kurs 2.50 svarende til maksimalt DKK 2.5 mio. i perioden 22. november – 1. december 2023, begge dage inklusive. I hele perioden har der været indlagt en synlig stående budordrer i kurs 2.50, så markedet løbende har kunne følge tilbagekøbets udvikling, og som det også fremgik af selskabsmeddelelse 30/2023, så stod alle insidere tilbage for selskabets aktionærer, så insidere som ønskede at sælge aktier kun kunne tilbagesælge aktier den sidste dag, dvs. fra og med fredag d. 1. december 2023 kl. 09.00. Resultatet af insidernes evt. frasalg vil fremgå af en separat meddelelse. Resultatet af aktietilbagekøbsprogrammet blev at selskabet har tilbagekøbt 19.687 aktier til kurs 2.50 svarende til DKK 49.217,50. Selskabet ejer pr. dags dato totalt 4.854.063 egne aktier svarende til 9,06 % af selskabets aktiekapital. Det samlede antal aktier i virksomheden er

Registration of share capital increase in IDEX Biometrics 1 Dec 20231.12.2023 17:30:00 CET | Press release

Reference is made to the notice on 21 November 2023 regarding employees having exercised 389,608 incentive subscription rights at NOK 0.15 per share. The capital increase has been registered and the shares will be delivered soonest. Following the issue, the company's share capital is NOK 209,551,597.20 divided into 1,397,010,648 shares, each with a nominal value of NOK 0.15. For further information contact: Marianne Bøe, Investor Relations E-mail: Tel: +47 918 00186 About IDEX Biometrics IDEX Biometrics ASA (OSE: IDEX) is a global technology leader in fingerprint biometrics, offering authentication solutions across payments, access control, and digital identity. Our solutions bring convenience, security, peace of mind and seamless user experiences to the world. Built on patented and proprietary sensor technologies, integrated circuit designs, and software, our biometric solutions target card-based applications for payments and digital authentication. As